Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006273 · ClinicalTrials.gov registry record · Phase 1
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
A Phase 1 study of Refractory Solid Tumors, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06006273: Recruiting Phase 1 study of Refractory Solid Tumors, sponsored by M.D. Anderson Cancer Center.
NCT06006273 is a Phase 1 study of Refractory Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 1,460-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06006273, a Phase 1 study of Refractory Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG Eribulin
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT06006273 shows while recruiting
NCT06006273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,460-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Refractory Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT06006273 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06006273 about?
NCT06006273 is a clinical study titled "A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors". To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
What is the current status of trial NCT06006273?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-08-16. Estimated completion is 2028-12-31.
What conditions does trial NCT06006273 study?
This clinical trial studies the following conditions: Refractory Solid Tumors.
What interventions are being tested in trial NCT06006273?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT06006273?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006273 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
COMPLETED · Phase 1
-
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
COMPLETED · Phase 1
-
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI